[Federal Register Volume 60, Number 28 (Friday, February 10, 1995)]
[Notices]
[Pages 7976-7977]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-3443]



-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
[Docket No. 95N-0032]


Drug Export; Visipaque<SUP>TM (Iodixanol) Injection 270 
Milligrams Iodixanol/Milliliter (mg I/mL) and 320 mg I/mL Supplied in 
50 mL Vial, 100 mL, 150 mL, and 200 mL Bottle

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing that 
Nycomed, Inc., has filed an application requesting approval for the 
export of the human drug Visipaque<SUP>TM (iodixanol) Injection 270 
milligrams iodixanol/milliliter (mg I/mL) and 320 mg I/mL supplied in 
50 mL vial, 100 mL, 150 mL, and 200 mL bottle to Canada.

ADDRESSES: Relevant information on this application may be directed to 
the Dockets Management Branch (HFA-305), Food and Drug Administration, 
rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857, and to the contact 
person identified below. Any future inquiries concerning the export of 
human drugs under the Drug Export Amendments Act of 1986 should also be 
directed to the contact person.

FOR FURTHER INFORMATION CONTACT: James E. Hamilton, Center for Drug 
[[Page 7977]] Evaluation and Research (HFD-310), Food and Drug 
Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2073.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of 
the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) 
provide that FDA may approve applications for the export of drugs that 
are not currently approved in the United States. Section 802(b)(3)(B) 
of the act sets forth the requirements that must be met in an 
application for approval. Section 802(b)(3)(C) of the act requires that 
the agency review the application within 30 days of its filing to 
determine whether the requirements of section 802(b)(3)(B) have been 
satisfied. Section 802(b)(3)(A) of the act requires that the agency 
publish a notice in the Federal Register within 10 days of the filing 
of an application for export to facilitate public participation in its 
review of the application. To meet this requirement, the agency is 
providing notice that Nycomed, Inc., 1250 South Collegeville Rd., P.O. 
Box 5000, Collegeville, PA 19426-0900, has filed an application 
requesting approval for the export of the human drug Visipaque<SUP>TM 
(iodixanol) Injection 270 mg I/mL and 320 mg I/mL supplied in 50 mL 
vial, 100 mL, 150 mL, and 200 mL bottle to Canada. The product is used 
in angiocardiography (left ventriculography, aortic root injections, 
and selective coronary arteriography) and can be used in the diagnosis 
of coronary artery disease as well as evaluation of the function of the 
chambers of the heart and heart valves. The application was received 
and filed in the Center for Drug Evaluation and Research on December 
28, 1994, which shall be considered the filing date for purposes of the 
act.
    Interested persons may submit relevant information on the 
application to the Dockets Management Branch (address above) in two 
copies (except that individuals may submit single copies) and 
identified with the docket number found in brackets in the heading of 
this document. These submissions may be seen in the Dockets Management 
Branch between 9 a.m. and 4 p.m., Monday through Friday.
    The agency encourages any person who submits relevant information 
on the application to do so by February 21, 1995, and to provide an 
additional copy of the submission directly to the contact person 
identified above, to facilitate consideration of the information during 
the 30-day review period.
    This notice is issued under the Federal Food, Drug, and Cosmetic 
Act (sec. 802 (21 U.S.C. 382)) and under authority delegated to the 
Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the 
Center for Drug Evaluation and Research (21 CFR 5.44).

    Dated: January 31, 1995.
Kathy P. Mirracco,
Acting Director, Office of Compliance, Center for Drug Evaluation and 
Research.
[FR Doc. 95-3443 Filed 2-9-95; 8:45 am]
BILLING CODE 4160-01-F